Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Buy Of India’s Ranbaxy Expected To Be Final By End Of Year

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo's purchase of India's largest drug maker, Ranbaxy Laboratories, is expected to be completed by the end of the year. Ranbaxy CEO Malvinder Singh said he expected the $4.6 billion deal to be completed by then, enabling the generics maker to strengthen its Indian business. Singh told reporters that despite the U.S. allegations it misbranded or adulterated some of its drugs shipped to the United States, the company is getting back to strength there. "I am looking at strengthening India business…," he said. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts